Fair Value of Financial Instruments - Change in Fair Value (Details) - USD ($)		6 Months Ended
	Apr. 18, 2022	Jun. 30, 2022	Jun. 30, 2021
Elusys Therapeutics
Change in fair value
Contingent consideration paid	$ 22,800,000
Contingent Consideration
Change in fair value
Balance at the beginning		$ 3,342,515
Change in fair value		(224,000)
Acquisition of Elusys		42,953,686
Payment of receivable consideration		(20,784,571)
Payment of deferred cash consideration		(2,000,000)
Balance at end		23,287,630
Contingent Consideration | Pelican Therapeutics, Inc.
Change in fair value
Balance at the beginning		3,342,515	$ 2,912,515
Change in fair value		(224,000)	111,000
Balance at end		3,118,515	3,023,515
Contingent Consideration | Elusys Therapeutics
Change in fair value
Acquisition of Elusys		42,953,686
Payment of receivable consideration		(20,784,571)
Payment of deferred cash consideration		(2,000,000)
Balance at end		20,169,115
Warrant Liability
Change in fair value
Balance at the beginning		11,020	33,779
Change in fair value		(9,290)	4,023
Balance at end		$ 1,730	$ 37,802